Alto Neuroscience
Alto Neuroscience, a US-based clinical-stage biopharma, develops precision medicines using AI-driven biomarkers.
- 72
- Private company
- Mountain View, CA, USUnited States
Alto Neuroscience, a US-based clinical-stage biopharma, develops precision medicines using AI-driven biomarkers.
altoneuroscience.comCrawled Oct 16, 2026
The company uses patients' neurobiology to predict therapeutic response and improve clinical success.
The company uses clinical and biological insights in psychiatric treatment.
The company uses brain biology to develop personalized treatments for patients and has job opportunities.
Dr. Adam Savitz has served as Chief Medical Officer since July 2021. Before joining the company, he held roles at Janssen Research and Development, LLC, including Senior Director Clinical Research and Clinical Strategy Leader for the Mood Disorder Disease Area Stronghold.
Erin McQuade has served as General Counsel and Chief Administrative Officer since February 2023. She previously held legal roles at Levo Therapeutics and Assertio Therapeutics, Inc.
Jessica Powell has served as Chief Development Officer since September 2023 and was previously Vice President, Clinical Operations from June 2022 to September 2023. Powell held roles at Alkahest, Inc. and was a Senior Clinical Project Manager at Bioclinica.
Dr. Madhukar Trivedi is a professor of psychiatry at the University of Texas Southwestern Medical Center. He serves as Chief of the Division of Mood Disorders and founding Director of the Center for Depression Research and Clinical Care.
The team includes experts in neuroscience and clinical psychology and works on personalized solutions for patients.
The page describes the company's approach to psychiatry and invites inquiries.
The company uses individuals' brain biology to develop personalized medicines intended to help patients get better faster.
Alto Neuroscience, Inc.'s privacy notice describes its privacy practices.
GitHubRepository owner